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Abstract
Background: We are reporting for the first time the in vivo anti-inflammatory activity of extracts and fractions, and in
vitro  anti-inflammatory activity of pure compounds, all isolated from Pseudopterogorgia elisabethae collected at the
Providencia (chemotype 1) and San Andrés (chemotype 2) Islands (SW Caribbean).
Methods: Extracts from P. elisabethae were fractionated on silica gel to yield fractions: F-1 (pseudopterosins PsQ, PsS
and PsU) and F-2 (amphilectosins A and B, PsG, PsK, PsP and PsT and seco-pseudopterosins seco-PsJ and seco-PsK) from
chemotype 1, and F-3 (elisabethatrienol, 10-acetoxy-9-hydroxy- and 9-acetoxy-10-hydroxy-amphilecta-8,10,12,14-
tetraenes (interconverting mixture) and amphilecta-8(13),11,14-triene-9,10-dione) from chemotype 2. By using
preparative RP-HPLC and spectroscopic means, we obtained the pure PsG, PsK, PsP, PsQ, PsS, PsT, PsU, seco-PsK and
the interconverting mixture of non-glycosylated diterpenes (IMNGD). The anti-inflammatory properties of extracts and
fractions were evaluated using in vivo model "12-O-tetradecanoyl-phorbol-acetate (TPA)-induced mouse ear oedema".
The activities of pure compounds and of the IMNGD were evaluated using in vitro assays myeloperoxidase (MPO) release
(by human polymorphonuclear neutrophils (PMNs)), nitric oxide release (by J-774 cells) and scavenger activity on NO.
Results: In the in vivo anti-inflammatory assay, extracts and F-3 showed low inhibition levels of inflammation compared
to indomethacin, F-1 and F-2. Additionally, we evaluated the MPO release to the inflammation site, and found a marked
inhibition of MPO levels by all extracts and fractions, even superior to the inhibition shown by indomethacin.
Furthermore, in the MPO in vitro assay, IMNGD, PsQ, PsS, PsT and PsU, exhibited higher inhibition levels compared to
dexamethasone and indomethacin. In the NO release in vitro, IMNGD, PsP and PsT were the most potent treatments.
Finally, because the PsG, PsP and seco-PsK did not exhibit any NO scavenger activity, they should inhibit the inducible
Nitric Oxide Synthase (iNOS) or other routes that influence this enzyme. Alternatively, PsQ, PsS, and PsU did show
scavenger activity.
Conclusion: All results presented contribute to demonstrate that the compounds isolated in this work from P.
elisabethae  are promising molecules with an interesting anti-inflammatory activity profile. Additionally, the results
obtained could provide preliminary insights towards their structure-activity relationship.
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Background
The pseudopterosins and seco-pseudopterosins, diterpene
glycosides isolated from the Caribbean gorgonian octoc-
oral Pseudopterogorgia elisabethae, have shown potent anti-
inflammatory and analgesic properties through in vitro
and in vivo assays [1-7], usually involving versatile modes
of action [4,8]. They have a particular interest due to their
superior anti-inflammatory properties compared to the
commercial drug indomethacin. Furthermore, these com-
pounds appear to inhibit eicosanoid biosynthesis by
inhibiting phospholipase A2 (PLA2), 5-lipoxygenase (5-
LO) and cycloxygenase (COX), degranulation of leuko-
cytes and the consequent liberation of lisosomal enzymes
[3,4].
At present, partially purified extracts from P. elisabethae
collected in the Bahama, rich in pseudopterosins are cur-
rently incorporated into several skin care preparations
marketed by Estée Lauder, due to their excellent anti-
inflammatory and analgesic properties [9].
Likewise, the pseudopterosins A-D have been licensed to
OsteoArthritis Sciences Inc., for medical use as anti-
inflammatory drugs. This pharmaceutical company has
completed preclinical tests and developed a potent deriv-
ative of PsA called methopterosin (OAS1000), which is in
clinical phase I/II trial as a wound healing and anti-
inflammatory agent [10,11].
The high degree of chemical variation between different
specimens of P. elisabethae collected at various sites in the
Caribbean region has been acknowledged by several
authors. So far, 17 pseudopterosins (PsA-PsO, PsX and
PsY) isolated from specimens collected in the Bahamas
[1,12,13], Bermuda [12], and the Florida Keys [5] have
been reported. The structurally related seco-pseudopter-
osins A-D have also been identified in Pseudopterogorgia
kallos collected near the Marquesas Keys in Florida [2], the
seco-PsE-G and seco-PsJ isolated from P. elisabethae col-
lected at the Long Key, Florida [2,14], and seco-PsH-I iso-
lated from P. elisabethae collected at the San Andrés Island
[6].
Recently, as a part of our continuous search for biologi-
cally active compounds from marine organisms, we eval-
uated the extracts from P. elisabethae collected at
Providencia and San Andrés Islands (SW Caribbean) by
LC-MS, and found two distinct chemotypes that were
characterized based on their pseudopterosin and related
compound compositions. This correlated well with the
geographical distribution [15]. Chemotype 1, found
almost exclusively in Providencia Island, was mainly char-
acterized by the presence of PsP-PsV, PsG and PsK, amphi-
lectosins A and B, and two seco-pseudopterosins (seco-PsJ
and seco-PsK) [16,17]. Chemotype 2, found in San Andrés
Island, was revealed to contain several non-glycosylated
diterpenes such as an elisabethatriene analog named by us
as elisabethatrienol, 10-acetoxy-9-hydroxy- and 9-ace-
toxy-10-hydroxy-amphilecta-8,10,12,14-tetraenes (iso-
lated as an interconverting mixture (IMNGD)) and
amphilecta-8(13),11,14-triene-9,10-dione, along with
smaller amounts of pseudopterosins [14,17]. As far as we
know, there is only one work reporting the anti-inflam-
matory activity of the PsQ as an inhibitor of both super-
oxide anion (O2
-) and thromboxane B2  (TXB2) both
produced by activated rat neonatal microglia in vitro [6].
So far still nothing has been published on the activity of
the other diterpenes isolated from specimens collected at
Providencia and San Andrés Islands.
We evaluated for the first time the anti-inflammatory
activity of pseudopterosins, seco-pseudopterosins and the
related IMNGD (Figure 1) isolated from the two chemo-
types of P. elisabethae collected at the Providencia and San
Andrés Islands (SW Caribbean) [16,17]. The extracts and
fractions from the two chemotypes were assayed using the
in vivo model "12-O-tetradecanoyl-phorbol-acetate (TPA)-
induced mouse ear oedema" [18]. Compounds PsG, PsK,
PsP, PsQ, PsS, PsT, PsU, seco-PsK and IMNGD were evalu-
ated using in vitro anti-inflammatory screenings as mye-
loperoxidase (MPO) assay (released by human
polymorphonuclear neutrophils (PMNs)) [19,20], nitric
oxide release (cell based assay) and scavenger activity on
this radical [21].
Methods
Extraction of coral material and isolation of compounds
Fragments of individual colonies of P. elisabethae were col-
lected by SCUBA (Ca. 20–30 m depth) at different sites of
Providencia and San Andrés Islands (SW Caribbean). Cor-
als were identified by Dr. M. Puyana and vouchers speci-
mens deposited at the invertebrate collection of Museo de
Historia Natural Marina Colombiana (MHNMC) at Insti-
tuto de Investigaciones Marinas de Punta Betín (INVE-
MAR), coded as INV CNI 1612–1616. The dried colony
fragments (30 g) from each location were extracted sepa-
rately with dichloromethane-methanol (1:1) mixture.
Resultant extracts were filtered and concentrated by rotary
evaporation to obtain dark green oily extracts. The extracts
were classified by their LC-MS profile as chemotype 1
(Providencia extract) and chemotype 2 (San Andrés
extract), according to our previous report [15]. Each
extract was subjected separately to silica gel column chro-
matography and eluted with 500 ml of each solvent mix-
ture of increasing polarity (hexane-diethyl ether 1:1, 2:8;
diethyl ether; diethyl ether-ethyl acetate 8:2, 1:1, 2:8; ethyl
acetate; ethyl acetate-ethanol 8:2, 1:1; 2:8 and ethanol) as
previously described [16,17]. Thus, we obtained fraction
1 (F-1) (eluted with diethyl ether-ethyl acetate 8:2) con-
taining PsQ (47.5%), PsS (7.0%), and PsU (44.2%), andJournal of Inflammation 2009, 6:5 http://www.journal-inflammation.com/content/6/1/5
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Chemical structures of compounds isolated from P. elisabethae Figure 1
Chemical structures of compounds isolated from P. elisabethae. F-1 and F-2: diterpenes isolated from chemotype 1. F-
3: diterpenes isolated from chemotype 2.Journal of Inflammation 2009, 6:5 http://www.journal-inflammation.com/content/6/1/5
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fraction 2 (F-2) (eluted with diethyl ether-ethyl acetate
2:8) containing amphilectosins A (4.8%) and B(4.9%),
PsG (28.3%), PsK (13.3%), PsP (19.7%) and PsT (11.6%)
and seco-PsJ (8.1%) and seco-PsK (6.7%) from chemotype
1; the fraction 3 (F-3) (eluted with hexane-diethyl ether
2:8) containing elisabethatrienol (6.7%), IMNGD (1:1)
(84.5%), amphilecta-8(13),11,14-triene-9,10-dione
(2.8%) and other minor diterpenes (6.0%) were obtained
from chemotype 2. Final purification of all compounds
was performed on RP-HPLC, using MeOH-water (9:1) as
mobile phase with a 1.0 ml/min flow rate. The isolated
compounds were carefully identified by spectrospic
means according to the procedure described in our earlier
publications [16,17] and their purity checked by HPLC
and 13C NMR including DEPT.
Laboratory animals
Eight to ten week old ICR mice (35–42 g) of both sexes
were purchased from the animal center at the Departa-
mento de Farmacia, Universidad Nacional de Colombia.
All mice were acclimatized under standard laboratory
conditions, kept alternatively at 12 h of light and darkness
and fed with food and water ad libitum. Room temperature
was maintained at 20 ± 2°C. Animal experiments were
carried out in accordance with the criteria outlined in
"Guide for the Care and Use of Laboratory Animals" [22]
approved by the local Animal Ethical Committee and the
guide 008430 of 1993 issued by the Health Department
of Colombia [23].
Drugs
The following substances were purchased from Sigma (St
Louis, USA): 12-O-tetradecanoyl-phorbol-acetate (TPA),
indomethacin, dexamethasone, L-NIO, curcumin, hexa-
decyltrimethylammonium bromide (HTAB), tetramethyl-
bencidine, hydrogen peroxide, formaldehyde,
dimethylformamide, sodium nitroprusside, sodium ace-
tate, sulfanilamide, lipopolysaccharide (LPS) from
Escherichia coli, Hanks' balanced salt solution (HBSS),
Dulbecco's modified Eagle's medium (DMEM), phos-
phate-buffered saline (PBS), fetal bovine serum (FBS),
gentamycin and calcium ionophore A23187. Ficoll-Paque
was purchased from ICN (USA) and organic solvents from
Merck Co. (Germany).
Cell culture and cell line J-774 preparation
The J774 murine macrophage cell line was maintained as
an adherent culture and was grown as a monolayer in a
humidified incubator (95% air; 5% CO2) at 37°C in 75
cm2 flasks containing DMEM supplemented with 10% (v/
v) FBS, and 50 μg/ml gentamycin [24]. The cells were
detached mechanically and viability was evaluated by
trypan blue exclusion assay.
Human polymorphonuclear neutrophils preparation
A sample of cells were obtained from the peripheral blood
of healthy subjects, and PMNs were extracted employing
the standard techniques of dextran sedimentation, centrif-
ugation on Ficoll-Paque (1.077 g/ml), and hypotonic lysis
of contaminating red blood cells. The cells were washed
twice and resuspended in HBSS and used immediately.
The PMNs purity was 98–100% (Turk exclusion test) and
viability ≥ 99%, as determined by the trypan blue exclu-
sion assay. All donors were non-smokers and none had
received medication for a period of 3 days prior to dona-
tion. Informed consent was obtained from all partici-
pants.
Topical anti-inflammatory activity
Topical anti-inflammatory activity of the extracts and frac-
tions of the two chemotypes was studied using the
method described by De Young [18]. Ten ICR mice were
used for each treatment group. Oedema was induced on
the right ear by topical application of 2.5 μg/ear of TPA in
acetone. The left ear was left untreated and used as con-
trol. Extracts, fractions and indomethacin (0.5 mg/ear)
were dissolved in acetone and applied to right ear simul-
taneously with TPA. Four hours after the inflammation
induction the animals were sacrificed and a biopsy (6 mm
diameter) of both ears (left and right) was performed. The
oedema was measured as an increase in ear thickness due
to the TPA agent application by difference in weight
between both ears. The inflammation inhibition percent-
age was evaluated as the weight difference between treated
and non- treated ears of each animal compared to the con-
trol group (vehicle).
Myeloperoxidase assay in mouse ear oedema tissues
Ear sections of each treatment were placed in 1 ml of PBS
pH 6.5 containing 0.5% HTAB and homogenized (45 s at
0°C) in a homogenizer (POLYTRON). The homogenate
was decanted in a microfuge tube and centrifuged at 1250
rpm at 4°C for 15 min. Triplicate 25 μl samples of the
resulting supernatant were added to 96 well microtitre
plates. For the assay, 125 μl of HBSS pH 7.4, 50 μl of PBS
pH 5.4 and 20 μl of 0.012% hydrogen peroxide were
added to the wells and the plates were incubated at 37°C
for 5 min. The reaction was started by adding 20 μl of 18
mM tetramethylbencidine in 8% aqueous dimethylfor-
mamide. Plates were incubated at 37°C for 3 min and
then the reaction was stopped by adding 30 μl of 1.5 M
sodium acetate, pH 3.0 [25]. Enzyme activity was deter-
mined colorimetrically using a BIORAD 550 microplate
reader set to measure absorbance at 620 nm and expressed
as the inhibition percentage of MPO levels determined as
the absorbance difference between the control group
(vehicle) and the treated group compared to the absorb-
ance observed in the control.Journal of Inflammation 2009, 6:5 http://www.journal-inflammation.com/content/6/1/5
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Myeloperoxidase assay in human polymorphonuclear 
neutrophils
This assay was performed as described previously by Bra-
dley et al. [25]. PMNs (2.5 × 106 cells/well) were sus-
pended in HBSS. Cell viability (>97%) was determined
with the 3- [4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetra-
zolium bromide (MTT) cytotoxicity assay. IMNGD (50
μg/ml), pure compounds (10 μM), indomethacin (10
μM) and dexamethasone (10 μM), were added to cells
and the mixture incubated at 37°C for 5 min. Subse-
quently, the cells were activated by calcium ionophore
A23187 (1 μM) and incubated at 37°C for an additional
10 min. The reaction was stopped by centrifugation (3000
rpm, 4°C and 15 min) and the enzyme activity in the
supernatant was determined as described above for MPO
assay in mouse ear oedema tissues.
Effect on NO production in J774 macrophages
Assay was carried out as described by CYTED [26]. The
J774 cells were plated in 96 well culture plates at a density
of 2.0 × 105 cells/well and allowed to adhere for 2 h in
DMEM supplemented with 5% FBS and gentamycin (50
μg/ml), and cultured at 37°C in humified 95% air, 5%
CO2. Thereafter the medium was replaced with fresh
medium and cells were activated by LPS (100 μg/ml) from
E. coli. Thirty minutes before LPS test IMNGD, pure com-
pounds, dexamethasone and L-NIO were added to cells at
various concentrations. After 18–20 h culture medium
was removed, centrifuged and the supernatant was used
for the determination of nitrite (NO2
-) production. Cell
viability (>95%) was determined with the Alamar blue
assay. NO2
- levels in culture media from J774 macro-
phages were measured 24 h after LPS or compound chal-
lenge with the Griess reaction [26]. After 5 min incubation
at room temperature the absorbance in the plate was
measured at 570 nm using a BIORAD 550 microplate
reader set. The results were expressed as the inhibition
percentage of NO measuring the absorbance difference
between absorbance of maximum levels of NO2
- (LPS
stimulated cells) compared to the absorbance of each
treatment.
Nitric oxide scavenger assay
Sodium nitroprusside in aqueous solution at physiologi-
cal pH spontaneously generates nitric oxide, which inter-
acts with oxygen to produce nitrite ions these can be
estimated by the use of Griess reagent as described previ-
ously by Marcocci et al. [27]. Scavengers of nitric oxide
compete with oxygen leading to reduced production of
nitric oxide. Sodium nitroprusside (5 μM) in PBS was
mixed with different concentrations of the IMNGD and
pure compounds dissolved in methanol and incubated at
25°C for 120 min. The samples were then reacted with
Griess reagent. The absorbance of the chromophore
formed during the diazotization of nitrite with naphthyl-
ethylenediamine was measured at 570 nm using a BIO-
RAD 550 microplate reader set and referred to the
absorbance of standard solutions of potassium nitrite
treated in the same way with Griess reagent. Curcumin
was used as positive control. The results were expressed as
scavenger percentage of NO, measuring the absorbance
difference between absorbance of maximum levels of NO
compared to the absorbance of each treatment.
Statistical analysis
Results are presented as mean ± standard error of mean
(S.E.M.). Data was subjected to descriptive statistics and
analysis of variance (ANOVA) and complemented by
Dunnett's post hoc test where appropriate. P < 0.05 was
considered as indicative of significance using GraphPad
Software, Prism V. 4.0.
Results
P. elisabethae anti-inflammatory activity in vivo 
evaluation
The TPA-induced ear oedema model is a classical experi-
mental model of acute inflammation which allows evalu-
ating the anti-inflammatory properties of extracts,
fractions and pure compounds, as well studying the pres-
ence of several anti-inflammatory mediators at the site of
the inflammation. In the present work, we determined,
using the mentioned model, the effect of extracts and frac-
tions of P. elisabethae (vide infra) on important events
related to the topical inflammatory process i.e. oedema
formation, and MPO release to the oedema tissues.
Topical anti-inflammatory activity and tissue MPO assay
The evaluation of the anti-inflammatory properties of
extracts (chemotype 1 and chemotype 2) and fractions, F-
1 containing pseudopterosins (PsQ, PsS and PsU), F-2
containing amphilectosins A and B, pseudopterosins
(PsG, PsK, PsP and PsT) and seco-pseudopterosins (seco-
PsJ and seco-PsK) and F-3 containing non-glycosylated dit-
erpenes (elisabethatrienol, IMNGD, amphilecta-
8(13),11,14-triene-9,10-dione and other minor diterpe-
nes), isolated from P. elisabethae using the TPA-induced
mouse ear oedema is shown in Figure 2. As can be seen in
this figure, topical application on the mouse ear oedema
of both extracts showed relatively low levels inflamma-
tion inhibition of 21 ± 2%, and 31 ± 2%, respectively,
when compared to the activity showed by the anti-inflam-
matory commercial drug indomethacin (78 ± 3%), used
as reference in this assay. In contrast, F-1, F-2 and F-3
exhibited inhibition levels of 62 ± 3%, 65 ± 4% and 40 ±
3%, respectively, on the TPA-induced oedema, compara-
ble to that shown by the indomethacin (78 ± 3%).
MPO assay may be used as an indirect marker of PMNs
activation at the site of the inflammatory process [28]. In
this context, we analyzed the effect of TPA and concomi-Journal of Inflammation 2009, 6:5 http://www.journal-inflammation.com/content/6/1/5
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tant applications and F-1, F-2 and F-3 fractions on the
activity of MPO in the mouse ear oedema exudates (Figure
3), after a 4 h treatment. In these experiments we found a
marked inhibition of the enzyme activity by the two
extracts and fractions tested, indicating high inhibition of
neutrophil migration to the site of inflammatory, superior
to the inhibition shown by the indomethacin (72 ± 6%).
P. elisabethae anti-inflammatory activity in vitro 
evaluation
An important aspect that must be taken into account in
the screening of anti-inflammatory compounds concerns
the in vitro assays utilized and the prediction of the effi-
cacy of test compounds in vivo in order to define their pos-
sible clinical relevance. The inflammation is a complex
process characterized by the contribution of several medi-
Effects of extracts and fractions (0.5 mg/ear) from P. elisabethae with respect to vehicle (acetone), on the TPA-induced mouse  ear oedema Figure 2
Effects of extracts and fractions (0.5 mg/ear) from P. elisabethae with respect to vehicle (acetone), on the TPA-
induced mouse ear oedema. Data expressed as mean ± S.M.E., n = 10 (Anova post-test Dunnet: *P < 0.05, **P < 0.01 and 
***P < 0.001 respect to indomethacin (0.5 mg/ear)).
Effects of extracts and fractions from P. elisabethae with respect to vehicle on MPO levels in supernatants of homogenates from  TPA-treated ears Figure 3
Effects of extracts and fractions from P. elisabethae with respect to vehicle on MPO levels in supernatants of 
homogenates from TPA-treated ears. Data expressed as mean ± S.E.M., n = 3 (Anova post-test Dunnet: P > 0.05 respect 
to indomethacin).Journal of Inflammation 2009, 6:5 http://www.journal-inflammation.com/content/6/1/5
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ators including MPO and NO [19,21,29]. In the present
work we determined the effect of IMNGD and pure com-
pounds from P. elisabethae on the inhibition of MPO
released in human PMNs and the NO production in J774
macrophages and also the NO scavenger activity.
Inhibition of MPO released by activated human PMNs
The neutrophil granulocyte is a central component of the
inflammation process, and has the ability to migrate to
the inflammation site and to release toxic products capa-
ble of killing invading pathogens. Among the mentioned
toxic products, MPO enzyme system is considered to be
part of an important antimicrobial system [19] released
into the phagosome during the neutrophil degranulation.
Thus, we measured the activity of IMNGD and pure com-
pounds from P. elisabethae on the release of MPO enzyme
on human PMNs using in vitro experiments as well. Previ-
ously, (data not shown) we established experimentally
through MTT cytotoxicity assay that cell viability of
human PMNs (>97%) was affected by neither the pure
compounds used (up to 10 μM) nor by IMNGD (up to 50
μg/ml) evaluated.
Figure 4 shows the percentage of MPO inhibition
(released in vitro by human PMNs) by IMNGD (10 μg/ml)
and pure compounds (10 μM) isolated from P. elisabethae.
IMNGD was the most active treatment in the experiment,
exhibiting 92 ± 6% inhibition levels in comparison with
indomethacin (57 ± 4%) and dexamethasone (35 ± 1%).
In this assay (Figure 4), PsQ (59 ± 4%), PsS (49 ± 4%), PsT
(52 ± 4%) and PsU (52 ± 4%) showed similar activity
compared to the reference drug indomethacin (57 ± 4%).
PsG and seco-PsK showed moderate activity, 34 ± 12% and
23 ± 5%, respectively. PsK and PsP were the only pseudop-
terosins that did not display any activity in this model.
Inhibition of NO released in J774 macrophages
Nitric oxide has been shown to have the ability to stimu-
late COX-2 showing a potential synergism [30]. Nitric
oxide appears to be of crucial importance and, this may be
considered as a rewarding target for intervention. With
this perspective, the present experiment was designed in
murine macrophage cells to investigate whether the
IMNGD and pure compounds isolated from P. elisabethae
have any effect on NO production to combat the inflam-
matory challenge, which is the possible mechanism
underlying such an effect. The total NO production in
J774 macrophages is an indicator of NO synthesis, an
event that occurs during the inflammation process.
In preliminary experiments (data not shown) we estab-
lished that cell viability (>95%) was affected by neither
the pure compounds used (up to 10 μM) nor by the
IMNGD (up to 25 μg/ml).
Figure 5 shows the inhibition of NO released in murine
macrophages (J-774 cell line) exerted by the IMNGD and
pure compounds isolated from P. elisabethae. IMNGD at 5
μg/ml had moderate activity (35 ± 5%), but at 25 μg/ml it
exhibited an excellent activity with inhibition levels close
to 80%. PsP and PsT were the most potent treatments
exhibiting inhibition levels between 58–52% at 10 μM
and 50–38% at 1 μM, respectively. PsG, PsK, PsQ, PsS,
PsU and seco-PsK showed low activity (aprox. 25%) even
at the highest concentration (10 μM).
NO scavenger activity
NO, by inhibiting the generation of pro-inflammatory lip-
ids, exerts anti-inflammatory effects. However, the simul-
taneous and sustained production of NO and O2
- leads to
the production of toxic species in certain environment,
and may cause the reversal of NO effects from protective
to deleterious [31]. Thus, the scavenger activity of reactive
nitrogen species seems to be important in determining the
anti-inflammatory or inflammatory role for NO. In the
present experiment, the scavenger effect of IMNGD and
pure compounds from P. elisabethae on NO was investi-
gated.
Figure 6 shows the scavenger activity of IMNGD and pure
compounds isolated from P. elisabethae. The PsQ, PsS and
PsU at concentration of 10 μM, exhibited potential NO
scavenger percentage of 42 ± 3%, 31 ± 6% and 38 ± 4%,
respectively. In contrast, IMNGD, PsK and PsT showed
scavenger activity as low as 25%. PsG, PsP and seco-PsK
did not have any scavenger activity.
Effects of pure compounds from P. elisabethae on MPO  release in PMNs Figure 4
Effects of pure compounds from P. elisabethae on 
MPO release in PMNs. Calcium ionophore (1 μM) 
(A23187)-PMNs (2.5 × 106 cells/well) treated with IMNGD 
(50 μg/ml), pure compounds (10 μM), dexamethasone (10 
μM) and indomethacin (10 μM). Data expressed as mean ± 
S.E.M., n = 3 (Anova post-test Dunnet: *P < 0.05 and **P < 
0.01 respect to control (stimulated cells).Journal of Inflammation 2009, 6:5 http://www.journal-inflammation.com/content/6/1/5
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Discussion
The results of the present paper clearly indicates that top-
ical application of the extracts (chemotype 1 and chemo-
type 2) and fractions F-1 (mixture of pseudopterosins) F-
2 (mixture of pseudopterosins, seco-pseudopterosins and
amphilectosins) and F-3 (mixture non-glycosylated diter-
penes) isolated from P. elisabethae (Figure 1), and the anti-
inflammatory drug indomethacin resulted in a significant
inhibition of two important events related to the topical
inflammatory response induced by TPA, oedema forma-
tion, and PMNs infiltration and degranulation, events
that modulate MPO levels at inflammation site. There-
fore, these results consistently support that the com-
pounds present in the mentioned fractions possess
Effects of pure compounds from P. elisabethae on NO release by LPS-stimulated J774 macrophages Figure 5
Effects of pure compounds from P. elisabethae on NO release by LPS-stimulated J774 macrophages. Data 
expressed as mean ± S.E.M., n = 3. (Anova post-test Dunnet: *P < 0.05 and **P < 0.01 respect to control (stimulated cells).
NO scavenger activity with respect to control showed by pure compounds from P. elisabethae Figure 6
NO scavenger activity with respect to control showed by pure compounds from P. elisabethae. Data expressed as 
mean ± S.E.M., n = 3. (Anova post-test Dunnet: *P < 0.05 and **P < 0.01 respect to control (maximum NO release).Journal of Inflammation 2009, 6:5 http://www.journal-inflammation.com/content/6/1/5
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excellent topical anti-inflammatory properties, similar to
as was previously reported for other pseudopterosins as
PsA-D [1] and PsM, PsN and PsO [5].
The MPO decrease level even down to basal levels (Figure
3) confirms that the compounds present in the assayed
extracts and fractions can reduce the leukocyte infiltra-
tion. This was verified on ear homogenates. Based on
these results we evaluated in vitro whether the pure pseu-
dopterosins and seco-pseudopterosin (isolated from F-1,
F-2) and IMNGD (isolated from F-3) could have inhibi-
tion actions on cellular functions in human PMNs.
Initially, we evaluated leukocyte degranulation of calcium
ionophore A23187 stimulated cells (Figure 4). The
biomarker used was MPO since this is a recognized gran-
ular enzyme engaged in events of activation of PMNs and
is associated with tissue injury. Therefore, this is necessary
to form the strong oxidant hypoclorous acid, which by
reaction with superoxide can in turn generate the reactive
hydroxyl radical. In these assays PsQ, PsS, PsT and PsU
inhibited significantly the release of MPO in a similar way
as the positive controls indomethacin and dexametha-
sone. In contrast, the IMNGD showed superior inhibition
as compared to the positive controls suggesting that glyc-
osylated conditions could reduce the inhibitory activity of
these molecules. These results confirm the potential of
these molecules and the possibility that they contribute to
the inhibition of neutrophil-mediated tissue injury.
Additionally, by comparing the different MPO inhibition
values (Figure 4) for the tested compounds in terms of
chemical structure, interesting structure-activity relation-
ships arise. First of all, the comparison of the activity of
pseudopterosins with different sugar moiety linked to dit-
erpene may indicate that activity depends on: 1) kind of
sugar moiety, 2) whether sugar moiety is in a free form or
acetylated, 3) acetylation position within the sugar moiety
and 4) glycosylation position. For example, PsT glyco-
sylated with non-acetylated arabinopyranose has more
activity than PsP which is glycosylated with non-
acetylated fucopyranose. Likewise, PsQ and PsS
(acetylated fucose as sugar moiety) have more activity
than PsP. With regards to the acetylation position, the
results showed that acetylation in C-4' of fucose moiety
could improve the activity – MPO inhibition value of PsQ
(acetylated in C-4') compared to that shown by PsS
(acetylated in C-2').On the other hand the glycosylation
position might affect the inhibitory activity profile. For
example, all pseudopterosins glycosylated in C-10 (PsQ,
PsS, PsT and PsU), except PsP, showed more activity than
PsG and PsK which are glycosylated in C-9. In the same
way, the stereochemistry could be a determinant factor in
the inhibition of MPO and leukocyte degranulation, since
the activity of PsG and PsK, both glycosylated with fucop-
yranose but with different stereochemistry in the aglycone
(Figure 1), showed different activity. More experiments in
relation to this theme should be done to confirm the
above discussion.
Regarding NO release in J-774 cell-based assay (Figure 5),
we found that the activity of IMNGD and all pure com-
pounds is concentration-dependent. Additionally,
IMNGD showed a major activity than the pseudopter-
osins and seco-pseudopterosin. Again as in the MPO assay,
the non-glycosylation improves the inhibition of NO
release.
By comparing the different NO inhibition values for
tested compounds (Figure 5), we also observed structure-
activity relationships as with the MPO assay. In general, in
this assay the inhibitory activity apparently depends on
the glycosylation position (i. e. activity of PsP versus PsG).
As to the stereochemistry of the aglycone, it does not seem
to be a determinant factor to improve the inhibition (i. e.
activity of PsG versus PsK). In contrast the skeleton type
might influence the activity. For example, the amphilec-
tane skeleton (PsP) has more inhibitory activity than the
serrulatane skeleton (seco-PsK). As was mentioned before,
more experiments have to be performed to support struc-
ture-activity relationships among these kinds of com-
pounds.
In aiming to understanding the behavior of these com-
pounds with respect to their potential as inhibitors of the
NO release, we carried out NO scavenger activity assay
(Figure 6) to determine whether the inhibition of NO lib-
eration within J-774 cells is produced by inhibition of
some molecular process in the cellular machinery (such
us inhibition of expression and activity of Inducible Nitric
Oxide Synthase (iNOS)), or whether the inhibition is due
to scavenger activity [21]. According to the results of these
assays, PsG, PsP and seco-PsK did not exhibit any scaven-
ger activity, suggesting the possibility that these com-
pounds may inhibit iNOS or other routes that influence
this enzyme.
PsQ, PsS, and PsU showed scavenger activity (Figure 6)
which let us to confirm that these compounds inhibit NO
release in macrophage cells by scavenger activity. How-
ever, it is important to carry out more studies in order to
confirm if these compounds might inhibit some molecu-
lar routes upstream from NO production in cells.
Conclusion
The results presented here demonstrate that the PsP, PsQ,
PsS, PsT and PsU isolated from chemotype 1 and the
IMNGD isolated from chemotype 2 are promising mole-
cules with an interesting anti-inflammatory activity pro-
file similar to other compounds of this kind previouslyJournal of Inflammation 2009, 6:5 http://www.journal-inflammation.com/content/6/1/5
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described. Additionally, all results confirm that P. elisa-
bethae colleted at Providencia and San Andrés Islands has
great value as a source of lead compounds with anti-
inflammatory properties.
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